Ralph E. Johnson

Ralph E. Johnson is affiliated with the University of Illinois at Urbana-Champaign in the United States. Their research primarily focuses on medicine, with a specific emphasis on infectious diseases, virology, emergency medicine, neurology, and molecular biology.

Their recent research encompasses key topics in HIV research and treatment, addressing HIV-related health complications and treatments as well as HIV/AIDS interventions. Additionally, their work touches on long-term effects of COVID-19, CRISPR and genetic engineering, and COVID-19 clinical research studies including mental health aspects related to the pandemic.

Some of the notable recent papers by Ralph E. Johnson include:

• Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV, 2021, published in Nature Communications
• Multi-stakeholder consensus on a target product profile for an HIV cure, 2020, published in The Lancet HIV
• Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach, 2020, published in Clinical Infectious Diseases
• The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals, 2020, published in Current Opinion in HIV and AIDS
• Non-Invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV, 2020, published in bioRxiv (Cold Spring Harbor Laboratory)

Frequent co-authors collaborating with Ralph E. Johnson include:

• Alan Landay
• Leila B. Giron
• Clovis S. Palmer
• Qin Liu
• Xiangfan Yin

Publications have appeared in a variety of venues, demonstrating engagement with different audiences within the field. Frequent publication venues include:

• Nature Communications
• The Lancet HIV
• Clinical Infectious Diseases
• Current Opinion in HIV and AIDS
• bioRxiv (Cold Spring Harbor Laboratory)

Ralph E. Johnson's work spans several interconnected fields of medical science, with a principal focus on infectious diseases and their treatment. The scientist contributes to the understanding of HIV and COVID-19 through research addressing biomarkers, treatment interruptions in clinical trials during the pandemic, and the assessment of coinfections and their outcomes.